复旦学报（医学版）
複旦學報（醫學版）
복단학보（의학판）
FUDAN UNIVERSITY JOURNAL OF MEDICAL SCIENCES
2009年
4期
413-416
,共4页
恶性肿瘤%心率变异性%自主神经
噁性腫瘤%心率變異性%自主神經
악성종류%심솔변이성%자주신경
malignant tumor%heart rate variability%autonomic nerve
目的 探讨心率变异性在恶性肿瘤患者诊疗中的临床意义.方法 回顾性分析187例住院患者动态心率变异性检查资料,分为治疗前组90例,化疗组45例和52例非恶性肿瘤组(对照组),对不同组别和组内不同肿瘤分期患者的每5分钟正常心动周期标准差的平均数(ASDNN5)、每5分钟正常心动周期的标准差(SDANN5)、24 h全部正常心动周期的标准差(SDNN)及正常相邻心动周期差值的均方的平均根(RMSSD)四项心率变异性指标进行组间和组内比较.结果 肿瘤治疗前组不同分期患者的心率变异有差异,两两比较显示治疗前组Ⅲ期及Ⅳ期患者ASDNN5、SDANN5、SDNN均低于同组Ⅰ期患者及对照组(P均<0.05);治疗前组Ⅲ期仅SDNN低于同组Ⅱ期患者(P<0.05);化疗组Ⅳ期患者SDANN5,SDNN低于治疗前组Ⅳ期患者(P<0.05).结论 恶性肿瘤患者分期越晚,心率变异性降低越明显.化疗会影响Ⅳ期肿瘤患者的自主神经功能,降低心率变异性.
目的 探討心率變異性在噁性腫瘤患者診療中的臨床意義.方法 迴顧性分析187例住院患者動態心率變異性檢查資料,分為治療前組90例,化療組45例和52例非噁性腫瘤組(對照組),對不同組彆和組內不同腫瘤分期患者的每5分鐘正常心動週期標準差的平均數(ASDNN5)、每5分鐘正常心動週期的標準差(SDANN5)、24 h全部正常心動週期的標準差(SDNN)及正常相鄰心動週期差值的均方的平均根(RMSSD)四項心率變異性指標進行組間和組內比較.結果 腫瘤治療前組不同分期患者的心率變異有差異,兩兩比較顯示治療前組Ⅲ期及Ⅳ期患者ASDNN5、SDANN5、SDNN均低于同組Ⅰ期患者及對照組(P均<0.05);治療前組Ⅲ期僅SDNN低于同組Ⅱ期患者(P<0.05);化療組Ⅳ期患者SDANN5,SDNN低于治療前組Ⅳ期患者(P<0.05).結論 噁性腫瘤患者分期越晚,心率變異性降低越明顯.化療會影響Ⅳ期腫瘤患者的自主神經功能,降低心率變異性.
목적 탐토심솔변이성재악성종류환자진료중적림상의의.방법 회고성분석187례주원환자동태심솔변이성검사자료,분위치료전조90례,화료조45례화52례비악성종류조(대조조),대불동조별화조내불동종류분기환자적매5분종정상심동주기표준차적평균수(ASDNN5)、매5분종정상심동주기적표준차(SDANN5)、24 h전부정상심동주기적표준차(SDNN)급정상상린심동주기차치적균방적평균근(RMSSD)사항심솔변이성지표진행조간화조내비교.결과 종류치료전조불동분기환자적심솔변이유차이,량량비교현시치료전조Ⅲ기급Ⅳ기환자ASDNN5、SDANN5、SDNN균저우동조Ⅰ기환자급대조조(P균<0.05);치료전조Ⅲ기부SDNN저우동조Ⅱ기환자(P<0.05);화료조Ⅳ기환자SDANN5,SDNN저우치료전조Ⅳ기환자(P<0.05).결론 악성종류환자분기월만,심솔변이성강저월명현.화료회영향Ⅳ기종류환자적자주신경공능,강저심솔변이성.
Objective To evaluate the clinical practical value of the heart rate viability test in the patients with malignant tumor during their therapies. Methods Totally 187 cases were analyzed and were divided into three different groups, which included 90 malignant tumor patients before therapy, 45 patients with chemotherapy and 52 non-malignant tumor cases (control group). We compared four HRV indexes(ASDNN5,SDANNS, SDNN and RMSSD) of the patients between the different groups as well as inside each group. Results There were statistical significances in the indexes of ASDNN5, SDANN5 and SDNN of patients at different stages before therapy, the three indexes of the stage Ⅲ group were lower than those of the stage Ⅰ group and the control group as well. The three indexes of the stage Ⅳ group compared with the stage Ⅰ group or the control group (P<0.05) were lower either. There was also statistical significances in SDNN between the stage Ⅲ and the stage Ⅱ of the before-therapy group (P< 0. 05). The indexes of SDANN5 and SDNN of the stage Ⅳ in the chemotherapy group were lower than those of the same stage in the before-therapy group(P<0.05). Conclusions The later the stage of malignant tumor patients is, the more the index of HRV declines. Chemotherapy may affect autonomic nerve function of stage Ⅳ patients with malignant tumor and decrease their HRV.
